TIFAB

Across TCGA pan-cancer cohorts, TIFAB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TIFAB data layer compared with 25 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TIFAB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TIFAB expression acts as an unfavorable survival marker.

STAD, THCA, and LUAD are the cancer types where TIFAB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
THCA	DFS	Median	All	0.161	0.829	.007	9	view →
LUAD	OS	Median	All	0.285	0.673	.035	3	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TIFAB–STAD (OS)

Open the STAD breakdown →